Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247528 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL22326119 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL5610030 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL5609718 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL25155317 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL30343954 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL5691047 | 0.76 | CYP2C9 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19CYP2A6 | |
| SCHEMBL16579379 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL5609979 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 | |
| SCHEMBL31360106 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1247655-B1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | MITSUI CHEMICALS INC (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1262966-B1 | Optical recording medium and novel azaporphyrin compound | MITSUI CHEMICALS INC (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-6969764-B2 | Mono-, di-, and triazaporphyrin compounds optionally in the form of a metal or metalloid complex | MITSUI CHEMICALS, INC. (JP) | 2005-11-29 | — | — | US | disclosed |
| EP-1180765-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS INC (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20030194646-A1 | Mono-, di-, and triazaporphyrin compounds optionally in the form of a metal or metalloid complex | MITSUI CHEMICALS, INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | ALDH1A1 838/4885CYP1A2 308/4885CYP2C9 167/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885CYP1A2 297/4885CYP2C9 690/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | ALDH1A1 2071/4885CYP1A2 2451/4885CYP2C9 1767/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | ALDH1A1 2128/4885CYP1A2 4073/4885CYP2C9 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.